Last reviewed · How we verify
Apixaban single dose
Apixaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation.
Apixaban is a direct Factor Xa inhibitor that blocks the coagulation cascade to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis and pulmonary embolism treatment and prevention, Acute coronary syndrome (in combination with antiplatelet therapy).
At a glance
| Generic name | Apixaban single dose |
|---|---|
| Also known as | Eliquis single dose |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Drug class | Direct Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Apixaban selectively inhibits Factor Xa, a serine protease critical in both the intrinsic and extrinsic coagulation pathways. By blocking Factor Xa activity, it prevents the generation of thrombin and subsequent fibrin clot formation, thereby reducing thrombotic events. This direct mechanism allows for predictable pharmacokinetics and oral bioavailability without requiring monitoring.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis and pulmonary embolism treatment and prevention
- Acute coronary syndrome (in combination with antiplatelet therapy)
Common side effects
- Bleeding
- Nausea
- Syncope
Key clinical trials
- Apixaban in Subjects With Peritoneal Dialysis (PHASE1)
- Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis (PHASE1)
- A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants (PHASE1)
- Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD) (PHASE4)
- Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress (PHASE4)
- Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human Subjects (PHASE1)
- inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT (PHASE4)
- A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apixaban single dose CI brief — competitive landscape report
- Apixaban single dose updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI